Howell andrea (29 resultados)

paperback. Condición: Good. Crease on cover*.

paperback. Condición: Very Good. Crease on cover and a few pages*.

Hardback. Condición: Very Good. xxvi + 383 pp. Cancer Drug Discovery and Development Rubber-stamped on front free endpaper. book.

Soft cover. Condición: Good - Some Wear. Reprint.

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: Sehr gut. Zustand: Sehr gut | Seiten: 428 | Sprache: Englisch | Produktart: Bücher | Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital ¿ Azienda Sanitaria Locale 21 of the Veneto Region ¿ and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.…

Condición: Used. pp. xxvi + 390 1st Edition.

Condición: Used. pp. xxvi + 390.

Condición: Used. pp. xxvi + 390.

Condición: New. In.

Taschenbuch. Condición: Neu. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy | Molecular Mechanisms and Clinical Applications | Andrea Bonetti (u. a.) | Taschenbuch | Cancer Drug Discovery and Development | xxvi | Englisch | 2016 | Humana | EAN 9781493957101 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.…

Condición: New. pp. 398.

Condición: New. The papers in this volume were presented at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy held in Verona, Italy, from November 30th to December 3rd 2007 The volume covers important issues related to platinum drugs. Editor(s): Bonetti, Andrea; Leone, Roberto; Leone, Roberto; Howell, Stephen B. Series: Cancer Drug Discovery and Development. Num Pages: 424 pages, 45 black & white tables, biography. BIC Classification: MJCL; MMG. Category: (G) General (US: Trade). Dimension: 235 x 155 x 22. Weight in Grams: 652. . 2016. Softcover reprint of the original 1st ed. 2009. Paperback. . . . . …

Paperback. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condición: New. The papers in this volume were presented at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy held in Verona, Italy, from November 30th to December 3rd 2007 The volume covers important issues related to platinum drugs. Editor(s): Bonetti, Andrea; Leone, Roberto; Leone, Roberto; Howell, Stephen B. Series: Cancer Drug Discovery and Development. Num Pages: 424 pages, 45 black & white tables, biography. BIC Classification: MJCL; MMG. Category: (G) General (US: Trade). Dimension: 235 x 155 x 22. Weight in Grams: 652. . 2016. Softcover reprint of the original 1st ed. 2009. Paperback. . . . . Books ship from the US and Ireland. …

Hardcover. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

62 pp.; 27 x 20.4 cm.; staple bound; black-and-white & color; edition size unknown; unsigned and unnumbered; offset-printed; March / April 1980 issue of Flash Art, edited by Giancarlo Politi and Helena Kontova. Contents include: "Barnett Newman," by Barbara Cavaliere; "Salvador Dali," by Laura Cherubini; "Demythization. The End of Nature and the Death of Art," by Rosario Assunto; "Interview with Clement Greenberg," by Ann Stubbs; "Flash Art New York," reviews by Barbara Cavaliere, Thomas Lawson, Douglas Blau, Valentine Tatransky, and Kim Levin; "Modern Painting and Modern Criticism in England," by Ian Bennett; "Style and Sensibility in British Painting," by Andrea Hill; "Recent British Painting. Future Space," by Adrian Searle; "Flash Art California," review by Richard Armstrong; "The Bewildered Image," by Achille Bonito Oliva; "Italy;" "American Avant-Garde Theater: The Eighties," by Mel Gordon; "Post Avant-Garde Theater in Italy. From Analysis deviance, from subjectivity to the 'show' (1975-1979)," by Giuseppe Bartolucci; "New York 1980," by John Howell; "Reviews," by Tim Maul, Douglas Blau, Andrea Hill, and Helena Kontova; "Switzerland," review by Christoph Schenker and "Flash Art Germany: Notizen," reviews by Annelie Pohlen, Ernst Busche, Heftige Malerei," by Ernst Busch. English translations, corrections, and editings by Michael Moore, Gwen Jones, and Nella Verducci. Cover: Barnett Newman. Very Good / Fine. Light dusting of covers with light edge wear and light sunning of covers. Contents clean and unmarked. Due to large size and weight additional shipping charges will be required for international orders.…

Paperback. Condición: Brand New. 200 pages. 9.69x7.44x0.46 inches. This item is printed on demand.

Weiters: Costa Oriental d'Africa. Província de Moçambique Reconhecimento hydrographico do Rio Chinde. 4 Karten Maßstab ca.1:18 650, Costa Oriental d'Africa Província de Mocambique Reconhecimento hydrographico do Rio Chinde,1890/Estudos do planalto do districto de Benguella. Perfil approximado do caminho percorrido entre Silva Porto e Ferreira de Almeida, na extensao recta de 386 kilometros / Alfredo Filippe de Andrade: Estudos do planalto do districto de Benguella. De Silva Porto (Bihe) a Ferreira d'Almeida (Mochico) por Alfredo Filippe de Andrade, Regente Agricola da Provincia. Maßstab 1.1.000.000. Der Fluss Limpopo bildet die Nordgrenze von Südafrika zu Botswana und Simbabwe.…

Condición: new. Questo è un articolo print on demand.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital - Azienda Sanitaria Locale 21 of the Veneto Region - and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use. 428 pp. Englisch.…

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital - Azienda Sanitaria Locale 21 of the Veneto Region - and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use. 428 pp. Englisch.…

Condición: New. Print on Demand pp. 398.

Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital ¿ Azienda Sanitaria Locale 21 of the Veneto Region ¿ and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 428 pp. Englisch.…

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital - Azienda Sanitaria Locale 21 of the Veneto Region - and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.Springer Nature Customer Service Center GmbH, Europaplatz 3, 69115 Heidelberg 428 pp. Englisch.…

Condición: New. PRINT ON DEMAND pp. 398.

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital - Azienda Sanitaria Locale 21 of the Veneto Region - and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.…

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital - Azienda Sanitaria Locale 21 of the Veneto Region - and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.…